<DOC>
	<DOCNO>NCT00841646</DOCNO>
	<brief_summary>The present study evaluate immunogenicity , safety tolerability two dos monovalent inactivated influenza vaccine adjuvanted MF59C.1 ( MF59 ) use surface antigen potential pandemic virus strain candidate ( H5N1 ) Adult Elderly Subjects .</brief_summary>
	<brief_title>Safety Immunogenicity Two Doses Monovalent Inactivated Influenza Vaccine That Adjuvanted With MF59C.1 ( MF59 ) Uses Surface Antigen From Potential Pandemic Virus Strain Candidate ( H5N1 ) Adult Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects age 18 year age old mentally competent sign informed consent form receive detailed explanation study protocol ; In good health determine : 1 . Medical history , 2 . Physical examination , 3 . Clinical judgment Investigator ; Able understand comply study procedure complete study diary , contact , available study visit . Previous receipt H5 vaccine ; Receipt another investigational agent within 4 week , completion safety followup period another study , whichever longer , prior enrollment unwilling refuse participation another clinical study end study ; Experienced acute disease infection require systemic antibiotic antiviral therapy ( chronic antibiotic therapy urinary tract prophylaxis acceptable ) within past 7 day ; Experienced fever ( defined axillary temperature 38.0Â°C ) within 3 day prior Visit 1 ; Pregnant breastfeeding ; Females childbearing potential refuse use acceptable method birth control duration study . Adequate contraception define hormonal ( e.g. , oral , injection , transdermal patch , implant , cervical ring ) , barrier ( e.g. , condom spermicide diaphragm spermicide ) , intrauterine device ( e.g. , IUD ) , monogamous relationship vasectomize partner vasectomize 6 month prior subject 's study entry ; Any serious disease , : 1 . Medically significant cancer , 2 . Autoimmune disease ( include rheumatoid arthritis diabetes mellitus type 1 ) , 3 . Medically significant diabetes mellitus type 2 , 4 . Medically significant chronic pulmonary disease , 5 . Medically significant acute progressive hepatic disease , 6 . Medically significant acute progressive renal disease ; 7 . Medically significant acute progressive neurological disease ; Surgery plan study period ; Bleeding diathesis ; Hypersensitivity egg , chicken protein , chicken feather , influenza viral protein , neomycin polymyxin component study vaccine ; History neurological symptom sign follow administration vaccine , anaphylactic shock follow administration vaccine ; Known suspect impairment/alteration immune function , example , result : 1 . Receipt immunosuppressive therapy ( systemic corticosteroid therapy cancer chemotherapy ) , Inhaled topical steroid allow 2 . Receipt immunostimulants , 3 . High risk develop immunocompromising disease ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Influenza vaccine</keyword>
</DOC>